KLOW Blend

Category: Blends · Last updated 2026-05-18

KLOW Blend is a four-component combinatorial research panel containing four distinct synthetic peptides co-lyophilized in a single 80 mg vial:

K — Kisspeptin-10 (Kiss-10; the C-terminal decapeptide fragment of kisspeptin-54)
L — Laminin-derived peptide (alternately, BPC-157 in some KLOW formulations · see Composition note below)
O — Oxytocin (the nonapeptide cyclic neurohormone)
W — GHK-Cu (the copper-binding tripeptide)

The blend is supplied as a single research-grade vial for combinatorial study design. Per-component peer-reviewed literature applies to each constituent; no peer-reviewed publication studies the four-component combination as a unit. This wiki cites the component literature only.

Peppudex card: see the mechanism + evidence-grade summary at [Peppudex / KLOW Blend](https://peppudex.com/peptides/klow-blend).

Composition note

The "KLOW" acronym is a trade-name convention rather than a regulated chemical designation, and ratios between the four components vary by supplier. The Peppu Studio vial contains the components in proportions documented on the per-batch Certificate of Analysis (CoA). Buyers using KLOW Blend in published research are advised to disclose the specific per-batch composition.

Per-component overview

Kisspeptin-10

Kisspeptin is the natural ligand of the GPR54 (KISS1R) receptor, a key upstream regulator of hypothalamic GnRH secretion and therefore the central node of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin-10 is the shortest active fragment, retaining receptor binding.

Laminin / BPC-157 (variant dependent)

Some KLOW formulations substitute a laminin-derived synthetic peptide (frequently a synthetic mimetic of the YIGSR sequence from the laminin β1 chain), while others substitute BPC-157 as the second component. The two have distinct mechanisms.

Oxytocin

The cyclic nonapeptide Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ produced endogenously in the hypothalamus. Receptor: oxytocin receptor (OXTR), a Gαq-coupled receptor expressed in uterine smooth muscle, lactating mammary tissue, and multiple central nervous system regions implicated in social bonding and stress response.

GHK-Cu

See the dedicated GHK-Cu article. Copper-binding tripeptide with extensive collagen-synthesis and skin-matrix-remodeling literature.

Mechanism (per component, not combined)

Kisspeptin-10: GPR54 agonism → GnRH pulse → LH/FSH downstream
Laminin-derived: cell-adhesion mimicry, integrin engagement
Oxytocin: OXTR Gαq signaling, central social and stress modulation
GHK-Cu: copper-peptide-mediated transcriptional modulation of remodeling genes

The combined pharmacology of the four-component blend has not been characterized in peer-reviewed publication.

See: Kisspeptin_receptor, Oxytocin_receptor, GHK-Cu, BPC-157.

Evidence

Per-component literature applies:

Kisspeptin-10 GPR54 binding: Kotani et al., J Biol Chem 2001 (KISS1 ligand identification).
Oxytocin receptor binding and central signaling: extensive 1980s–present literature.
GHK-Cu tissue remodeling: see the dedicated article.
BPC-157 (if substituted for laminin in the formulation): see the dedicated article.

No peer-reviewed publication studies the KLOW four-component combination as a unit. Combinatorial pharmacology of mixed-component peptide vials is challenging to publish because batch composition is not standardized across the field.

Dosing literature

This wiki does not recommend any human dose for the KLOW blend or any of its components. Per-component animal-model dose ranges from the underlying literature do not directly translate to a combined vial, because the per-component mass in any given KLOW vial depends on the supplier-specific ratios documented on the Certificate of Analysis.

Storage

Lyophilized: 2–8 °C protected from light, stable 12+ months. Reconstituted: 2–8 °C, use within 14 days (driven by the GHK-Cu component, which degrades faster than the others in solution). Protect from light. See Reconstitution.

Regulatory status

United States. Research use only. None of the four KLOW components is FDA-approved as a finished drug under this combinatorial label.
WADA. Per-component status varies. GHK-Cu is not on the prohibited list. Kisspeptin-10 and oxytocin are not currently on the prohibited list. BPC-157 (if included) is prohibited under Section S0.

References

Kotani M, Detheux M, Vandenbogaerde A, et al. "The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54." J Biol Chem. 2001;276(37):34631-6.
Pickart L, Margolina A. "Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data." Int J Mol Sci. 2018;19(7):1987. PMID 29986520.
Gimpl G, Fahrenholz F. "The oxytocin receptor system: structure, function, and regulation." Physiol Rev. 2001;81(2):629-83.

Research framing only. Peppu Wiki documents the published research literature surrounding peptide compounds. Articles describe in-vitro and animal-model evidence, regulatory status, and community-reported protocols. Nothing on this site is medical advice, a recommendation for human use, or a substitute for consultation with a qualified clinician. All compounds discussed are research-use only. Citations should be verified at the source before relying on any quantitative claim.

View edit history of this page